WHO seeks more documents from Bharat Biotech for emergency approval of Covaxin
The WHO has demanded additional documents amid government efforts to get Bharat Biotech’s Covaxin included in the World Health Organization’s (WHO) Emergency Use Listing (EUL). The World Health Organization has said that the company will have to give more information in order to list the covicin vaccine for emergency use. A document released on the WHO website states that Bharat Biotech submitted the Expression of Interest (EOI) on 19 April. In this regard, it will have to provide more information.
According to the document, a meeting in this regard is expected to be held in May-June 2021. The WHO has stated that if the product offered for evaluation meets the criteria for listing, its results will be published widely. The duration of the emergency use indexing process depends on the quality of the data presented by the vaccine-producing company and the data that meets the WHO criteria, the institution states.
At the same time, according to sources, Hyderabad-based Bharat Biotech International Limited has told the central government that it has already given 90 percent of the documents to the World Health Organization for listing the Covaxin vaccine for emergency use. . The remaining documents are expected to be submitted by June.
These vaccines are included in the EUL
Covaxin has not been included in the Emergency Use Listing (EUL) of the World Health Organization (WHO). In the midst of the threat of Corona, countries that have granted international travel exemptions have approved their own separate system or the vaccine approved by the WHO’s Emergency Use Listing. Currently, this list includes Moderna, Pfizer, AstraZeneca, Sinopharm and Covishield produced by Serum Institute of India. It is the effort of the government that India made Covaxin should also be included in this list as soon as possible.
